The University of Alabama at Birmingham Marnix E. Heersink School of Medicine, in collaboration with IN8bio, has discovered promising new data from a recent clinical trial.
It was unveiled at the American Society of Clinical Oncology's annual meeting in Chicago on June 5.
This trial is an investigator initiated open-label study being conducted by Dr. Burt Nabors at the O’Neal Comprehensive Cancer Center. The data comes from the Phase 1 clinical trial of INB-200 in patients with newly diagnosed glioblastoma multiforme. INB-200 is a genetically engineered gamma-delta T cell product candidate that is designed to be chemotherapy resistant as part of the company’s core Drug Resistant Immunotherapy platform.
“INB-200 continues to show promising activity in this challenging disease,” Dr. Trishna Goswami, chief medical officer of IN8bio, said in a release. “All patients have exceeded their expected PFS and some have exceeded expected OS even with poor prognostic factors such as MGMT unmethylated disease. We are particularly encouraged by patients in the repeated dose cohort that continue to do well, including one patient that has recently reached the one-year progression-free milestone, demonstrating durable stable disease and having returned to work.”
IN8bio was the first genetically modified gamma-delta T cell therapy to enter clinical trials. The Phase 1 trial of INB-200 completed enrollment of the first two cohorts with INB-200 being well-tolerated with no dose-limiting toxicities, cytokine release syndrome or neurotoxicity to date.
